JP7278776B2 - 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ - Google Patents

静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ Download PDF

Info

Publication number
JP7278776B2
JP7278776B2 JP2018554360A JP2018554360A JP7278776B2 JP 7278776 B2 JP7278776 B2 JP 7278776B2 JP 2018554360 A JP2018554360 A JP 2018554360A JP 2018554360 A JP2018554360 A JP 2018554360A JP 7278776 B2 JP7278776 B2 JP 7278776B2
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
cells
composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018554360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511553A5 (enExample
JP2019511553A (ja
Inventor
ビレンチク・マリア
フリッド・マイケル
クズネツォワ・アレクサンドラ
ガンキン・ユーリー
デューイ・マーク
Original Assignee
フェリシテックス・セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェリシテックス・セラピューティクス，インコーポレイテッド filed Critical フェリシテックス・セラピューティクス，インコーポレイテッド
Publication of JP2019511553A publication Critical patent/JP2019511553A/ja
Publication of JP2019511553A5 publication Critical patent/JP2019511553A5/ja
Application granted granted Critical
Publication of JP7278776B2 publication Critical patent/JP7278776B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018554360A 2016-04-15 2017-04-14 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ Active JP7278776B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323583P 2016-04-15 2016-04-15
US62/323,583 2016-04-15
PCT/US2017/027734 WO2017181087A1 (en) 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis

Publications (3)

Publication Number Publication Date
JP2019511553A JP2019511553A (ja) 2019-04-25
JP2019511553A5 JP2019511553A5 (enExample) 2020-06-11
JP7278776B2 true JP7278776B2 (ja) 2023-05-22

Family

ID=60039311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554360A Active JP7278776B2 (ja) 2016-04-15 2017-04-14 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ

Country Status (11)

Country Link
US (3) US10314843B2 (enExample)
EP (1) EP3443351A4 (enExample)
JP (1) JP7278776B2 (enExample)
KR (2) KR102494172B1 (enExample)
CN (1) CN109313197A (enExample)
AU (2) AU2017248807A1 (enExample)
BR (1) BR112018071023A2 (enExample)
CA (1) CA3020978A1 (enExample)
IL (2) IL292475A (enExample)
MX (2) MX2018012508A (enExample)
WO (1) WO2017181087A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322128B2 (en) 2016-04-15 2019-06-18 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026806A1 (en) 2011-08-19 2013-02-28 Exonhit Sa Dyrk1 inhibitors and uses thereof
US20150209359A1 (en) 2014-01-28 2015-07-30 Massachusetts Institute Of Technology Combination Therapies and Methods of Use Thereof for Treating Cancer
JP2015534584A (ja) 2012-10-10 2015-12-03 フェリシテックス・セラピューティクス，インコーポレイテッド 静止癌細胞の標的化による癌の治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2475368B1 (en) * 2009-09-11 2014-12-17 Amgen, Inc N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
FR2993317B1 (fr) 2012-07-16 2014-08-15 Snecma Carter de turbomachine dans un materiau composite et procede de fabrication associe
EA201600003A1 (ru) * 2013-06-11 2016-06-30 Байер Фарма Акциенгезельшафт КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА
CA2854542A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
MA39763A (fr) 2014-03-20 2017-01-25 Samumed Llc Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci
US20170304313A1 (en) 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
CN108135871B (zh) * 2015-07-23 2022-11-04 博蔚医药生物科技股份有限公司 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物
US10322128B2 (en) 2016-04-15 2019-06-18 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026806A1 (en) 2011-08-19 2013-02-28 Exonhit Sa Dyrk1 inhibitors and uses thereof
JP2015534584A (ja) 2012-10-10 2015-12-03 フェリシテックス・セラピューティクス，インコーポレイテッド 静止癌細胞の標的化による癌の治療
US20150209359A1 (en) 2014-01-28 2015-07-30 Massachusetts Institute Of Technology Combination Therapies and Methods of Use Thereof for Treating Cancer

Also Published As

Publication number Publication date
KR20230020560A (ko) 2023-02-10
KR20180130575A (ko) 2018-12-07
CA3020978A1 (en) 2017-10-19
EP3443351A1 (en) 2019-02-20
KR102494172B1 (ko) 2023-02-02
MX2022012146A (es) 2022-10-21
US20220110941A1 (en) 2022-04-14
IL262325A (en) 2018-11-29
IL262325B (en) 2022-06-01
BR112018071023A2 (pt) 2019-02-05
AU2017248807A1 (en) 2018-10-25
IL292475A (en) 2022-06-01
US10314843B2 (en) 2019-06-11
EP3443351A4 (en) 2019-12-18
US20190290651A1 (en) 2019-09-26
CN109313197A (zh) 2019-02-05
MX2018012508A (es) 2019-07-08
WO2017181087A1 (en) 2017-10-19
AU2023214240A1 (en) 2023-08-24
US20170296542A1 (en) 2017-10-19
JP2019511553A (ja) 2019-04-25

Similar Documents

Publication Publication Date Title
JP7278776B2 (ja) 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ
JP7123806B2 (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
WO2023140846A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
US10744133B2 (en) Compound for anti-cancer therapy that acts by targeting GOF mutant p53 and stimulates p73 to restore the p53 pathway signaling
AU2013235275A1 (en) Methods of treating cancer using aurora kinase inhibitors
MX2024013264A (es) Compuestos de 7-(pirimidin-4-il)quinolin-4(1h)-ona sustituidos como inhibidores de cinasas dependientes de ciclina
US20230226061A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
WO2017192665A1 (en) Inhibitors of ires-mediated protein synthesis
Terrana Synthesis and Biological Evaluation of New Small Molecules as Key Modulators to Overcome Cancer Drug Resistance
WO2017069913A1 (en) Chalcone compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230510

R150 Certificate of patent or registration of utility model

Ref document number: 7278776

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150